MIRA Pharmaceuticals: AI Ushering in New Era of Drug Discovery and Analysis
MIRA Pharmaceuticals (Nasdaq: MIRA) has released new data from artificial intelligence (AI) simulations showing that there may be significant potential advantages to the therapeutic potential of its drug candidate, MIRA1a, compared to plant-based medical marijuana. MIRA1a is a novel oral pharmaceutical marijuana currently being evaluated as a treatment for anxiety and cognitive decline associated with early-stage dementia.
Erez Aminov, Chief Executive Officer of MIRA Pharmaceuticals, said, “The results of our AI analysis work with InSilicoTrial’s efforts continue to validate MIRA1a as a potential pharmaceutical candidate within a multi-billion-dollar market to address the unmet needs of millions with anxiety and cognition issues with potentially fewer negative side effects than THC. Following positive results from recent in vivo animal testing and research indicating MIRA1a’s potential therapeutic effects, without the common negative side effects seen with THC even at high doses, we believe these targeted studies with InSilicoTrials employing artificial intelligence and machine learning further underscores MIRA1a’s position as a promising development in the evolution of neuropharmacological therapies.”
MIRA Pharmaceuticals is working towards filing an Investigational New Drug (IND) Application with the FDA.
Highlights
Adam Kaplin, MD, Ph.D., President and Chief Scientific Officer of MIRA Pharmaceuticals, said, “Through the lens of AI, one gains a more complete demonstration of MIRA1a’s potential properties at receptors that are not affected by THC. MIRA1a is uniquely positioned to potentially provide anti-anxiety effects, mitigate THC’s known side effects of increased appetite, and promote enhanced cognition, making it an exceptional candidate for addressing complex neuropsychiatric conditions.”
The simulations on MIRA1a were conducted in conjunction with the Company’s strategic collaboration with InSilicoTrials, a company specializing in leveraging AI and simulations to enhance drug and medical device development.
The AI simulation indicated MIRA1a’s potential to offer a superior anti-anxiety treatment, increased cognition and without the increased appetite associated with THC.
Anxiety Relief: The simulations suggest that MIRA1a’s agonistic action on the 5-HT1a receptor aligns with established anxiolytic properties in medications like Buspirone and certain SSRIs.
Appetite Concerns: The analysis reveals MIRA1a’s interaction with the 5-HT2c receptor, suggesting its potential to avoid the appetite related side effects often linked to THC.
Cognitive Enhancement: MIRA1a’s engagement with the Dopamine D1 receptor suggests a potential pathway for cognitive enhancement.
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The Company’s novel oral pharmaceutical marijuana, MIRA1a, is currently under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. MIRA1a, if approved by the FDA, could mark a significant advancement in addressing various neuropsychiatric, inflammatory, and neurologic diseases and disorders.
